David Boulton

David Boulton

AstraZeneca, Sweden - Södertälje / Sweden
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4399892
-
person_outline David Boulton's MOST POPULAR ARTICLES
1-) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetesMC Petrie, S Verma, KF Docherty, SE Inzucchi, I Anand, J Bělohlávek, ...Jama 323 (14), 1353-1368, 20204732020
2-) Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesisKM Hallow, G Helmlinger, PJ Greasley, JJV McMurray, DW BoultonDiabetes, Obesity and Metabolism 20 (3), 479-487, 20184722018
3-) Dapagliflozin, a novel SGLT2 inhibitor, induces dose‐dependent glucosuria in healthy subjectsB Komoroski, N Vachharajani, D Boulton, D Kornhauser, M Geraldes, L Li, ...Clinical Pharmacology & Therapeutics 85 (5), 520-526, 20094462009
4-) Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetesRA DeFronzo, M Hompesch, S Kasichayanula, X Liu, Y Hong, M Pfister, ...Diabetes care 36 (10), 3169-3176, 20133612013
5-) In vitro P-glycoprotein affinity for atypical and conventional antipsychoticsDW Boulton, CL DeVane, HL Liston, JS MarkowitzLife sciences 71 (2), 163-169, 20023192002